Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $170.00

Kymera Therapeutics (NASDAQ:KYMR) had its price target boosted by equities researchers at Guggenheim from $135.00 to $170.00 in a research report issued on Monday, MarketBeat.com reports. The firm currently has a “buy” rating on the stock. Guggenheim’s target price would suggest a potential upside of 43.88% from the stock’s previous close.

KYMR has been the topic of several other reports. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their price objective for the stock from $106.00 to $115.00 in a research report on Monday, July 13th. Barclays raised their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Truist Financial lifted their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Mizuho upped their price target on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Finally, BTIG Research reiterated a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $128.70.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $118.15 on Monday. The stock has a fifty day moving average price of $112.78 and a 200 day moving average price of $93.71. The stock has a market cap of $9.82 billion, a PE ratio of -36.47 and a beta of 1.95. Kymera Therapeutics has a 1 year low of $39.84 and a 1 year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. During the same quarter in the prior year, the company earned ($0.95) earnings per share. Kymera Therapeutics’s revenue was up 465.2% compared to the same quarter last year. As a group, equities research analysts predict that Kymera Therapeutics will post -3.78 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bruce Booth sold 31,283 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the sale, the director owned 461,794 shares of the company’s stock, valued at $50,557,207.12. This trade represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Noah Goodman sold 3,389 shares of Kymera Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total value of $387,328.81. Following the sale, the insider owned 47,179 shares of the company’s stock, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 3,587,629 shares of company stock valued at $386,183,782. 15.98% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics in the fourth quarter valued at approximately $63,000. Finally, Osaic Holdings Inc. increased its position in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.